ArticleFrontiers in medicine2026

Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series.

Yongjin Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.